Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COXEN Genomic Based Therapy in Advanced Urothelial Carcinoma
NCT02788201Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Percentage of Participants Who Enrolled and Underwent a Biopsy Who Went on to Receive Treatment Within 21 Days. Started Mar 2017; status: completed.
02
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02788201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788201.